Item 8.01 Other Events.
On January 28, 2020, Biohaven Pharmaceutical Holding Company Ltd. (the
"Company") entered into an underwriting agreement (the "Underwriting Agreement")
with Goldman Sachs & Co. LLC in connection with the registered public offering
("Offering") of up to 5,555,554 of the Company's common shares, including the
underwriter's option to purchase 724,637 additional shares, at a price to the
public of $51.75 per share. The aggregate gross proceeds to the Company from the
Offering, before deducting underwriting discounts and commissions and offering
expenses payable by the Company and before any exercise of the underwriter's
option, were approximately $250 million.
The Underwriting Agreement contains customary representations, warranties and
agreements of the Company, conditions to closing, indemnification rights and
obligations of the parties and termination provisions. A copy of the
underwriting agreement is attached as Exhibit 1.1 to this Current Report on Form
8-K and incorporated by reference herein.
On January 30, 2020, the Company issued and sold 4,830,917 of its common shares
pursuant to the Underwriting Agreement. The Offering was made pursuant to an
effective shelf registration statement (the "Registration Statement") filed with
the Securities and Exchange Commission on June 17, 2019 (File No. 333-232167), a
base prospectus, dated June 17, 2019, included as part of the Registration
Statement, and a prospectus supplement, dated January 28, 2020, filed with the
Securities and Exchange Commission pursuant to Rule 424(b) under the Securities
Act of 1933, as amended. A copy of the opinion of Maples & Calder relating to
the issuance of the common shares in the Offering is attached hereto as Exhibit
5.1 to this Current Report on Form 8-K. Exhibits 1.1 and 5.1 hereto are hereby
incorporated by reference into the Registration Statement.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
 Number                             Exhibit Description
  1.1        Underwriting Agreement, dated as of January 28, 2020, by and between
           the Company and Goldman Sachs & Co. LLC.
  5.1        Opinion of Maples & Calder.
  101      Pursuant to Rule 406 of Regulation S-T, the cover page information is
           formatted in iXBRL (Inline eXtensible Business Reporting Language).
  104      Cover Page Interactive Data File (formatted in iXBRL in Exhibit 101).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses